polymers-logo

Journal Browser

Journal Browser

Advanced Polymeric Nanomedicine for Drug Delivery Systems

A special issue of Polymers (ISSN 2073-4360). This special issue belongs to the section "Biobased and Biodegradable Polymers".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 437

Special Issue Editor


E-Mail Website
Guest Editor
University of Nebraska Medical Center, Fred & Pamela Buffett Cancer Center, 986849 Nebraska Medical Center, Omaha, NE 68198-6849, USA
Interests: drug delivery; anticancer therapy; slef-asselmbly; macromolecular drug; siRNA-delivery

Special Issue Information

Dear Colleagues,

Nanotechnology has an enormous impact on current nanomedicine-based drug and gene delivery systems. Biodegradable and biocompatible nanomaterials with an appropriate size and surface chemistry are paving the way for the advancement of drug and gene delivery systems. In the year 2020, consecutive approval (by FDA) of two nanomedicine formulations, mRNA-1273 and Tozinameran®, further underlined the potentiality of nanomedicine. 

Hence, in this Special Issue, we focus on nanomedicine-based drug and gene delivery systems executed for various therapeutic applications, including anticancer and antimicrobial therapies. Papers on biomaterials such as natural and synthetic polymers, peptides, and lipid-based nanomedicine are invited for publication in this issue. However, research works based on newly developed nanoformulations or nanomedicine with potential therapeutic effects toward a broad spectrum of diseases are also encouraged in this Special Issue.  

Dr. Sudipta Panja
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Polymers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • drug delivery
  • anticancer therapy
  • self-assembly
  • antimicrobial therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop